12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

APL-130277: Phase I data

Top-line data from a placebo-controlled Phase I trial in 15 healthy volunteers showed that a majority of patients receiving sublingual 3 mg APL-130277 achieved maximum plasma concentrations within 20 minutes...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >